Bevacizumab improves the delivery and efficacy of paclitaxel

Anti-Cancer Drugs

Volumn 21, Issue 7, 2010, Pages 687-694

  Yanagisawa, Mieko ^a   Yorozu, Keigo ^a   Kurasawa, Mitsue ^a   Nakano, Kohnosuke ^a   Furugaki, Koh ^a   Yamashita, Yoriko ^a   Mori, Kazushige ^a   Fujimoto Ouchi, Kaori ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

bevacizumab; breast cancer; combination therapy; drug delivery to tumor; lung cancer; paclitaxel; vascular permeability; xenograft model

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CELL CULTURE; CELL DENSITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL MEMBRANE PERMEABILITY; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MICE; PACLITAXEL; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954658288     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833b7598     Document Type: Article

References (18)

1. Presta LG, Chen H, O'Connor SJ, Chishlm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599.
2. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7:53-64.
3. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody, in vitro. Angiogenesis 2004; 7:335-345.
4. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-844.
5. Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671-680.
6. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13:134-136.
7. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550. (Pubitemid 44917502)
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
10. Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 2005; 11:8208-8212.
11. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-1986.
12. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CYC, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13:3942-3950.
13. Lee CG, Heijin M, di Tomaso E, G-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-5570.
14. Willet CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
15. Fandes HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 1977; 14:27-36.
16. Verheul HMW, Hammer H, van Erp K, Wei Y, Sanni T, Salumbides B, et al. Vascular endotherial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotropic murine renal cell cancer model. Clin Cancer Res 2007; 13:4201-4208.
17. Lu C, Thaker PH, Lin Yvonne G, Spannuth W, Landen CN, Merritt WM, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008; 4:477e1-477e10.
18. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere). Int J Cancer 2003; 104:121-129.